T&K: Wholly-owned subsidiary Huabo Kaisheng intends to win the bid for the national centralized procurement of drugs

Zhitong
2025.10.29 10:20

T&K announced that its wholly-owned subsidiary Shandong Huabo Kaisheng Biotechnology Co., Ltd. participated in the bidding for the 11th batch of national centralized drug procurement. According to the "Public Announcement of Proposed Selected Results for National Drug Centralized Procurement" issued by the National Organization for Drug Joint Procurement Office, Huabo Kaisheng's products are proposed to be selected for this centralized procurement. Among them, Fumaric Acid Lurasidone Tablets are suitable for symptomatic treatment of allergic rhinitis and urticaria in adults and adolescents, with a specification of 10mg, packaged as 28 tablets/box, and the proposed selected price is 30.49 yuan/box; Alendronate Sodium Tablets are suitable for the treatment of osteoporosis to prevent hip and spinal fractures, with a specification of 70mg, packaged as 4 tablets/box, and the proposed selected price is 6.2 yuan/box

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer